Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Global Optic Neuropathy Market 2016 Share, Trend, Segmentation and Forecast to 2022

Monday, October 10, 2016 3:24
% of readers think this story is Fact. Add your two cents.

(Before It's News)


Global Markets Direct’s, ‘Optic Neuropathy – Pipeline Review, H2 2016’, provides an overview of the Optic Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects.

Complete report details @

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Optic Neuropathy 
- The report reviews pipeline therapeutics for Optic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Optic Neuropathy therapeutics and enlists all their major and minor projects 
- The report assesses Optic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Optic Neuropathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Optic Neuropathy 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Optic Neuropathy pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Request a sample report @

Key points in table of content

Table of Contents 
Table of Contents 2 
List of Tables 5 
List of Figures 5 
Introduction 6 
Global Markets Direct Report Coverage 6 
Optic Neuropathy Overview 7 
Therapeutics Development 8 
Pipeline Products for Optic Neuropathy – Overview 8 
Pipeline Products for Optic Neuropathy – Comparative Analysis 9 
Optic Neuropathy – Therapeutics under Development by Companies 10 
Optic Neuropathy – Therapeutics under Investigation by Universities/Institutes 11 
Optic Neuropathy – Pipeline Products Glance 12 
Late Stage Products 12 
Clinical Stage Products 13 
Early Stage Products 14 
Optic Neuropathy – Products under Development by Companies 15 
Optic Neuropathy – Products under Investigation by Universities/Institutes 16 
Optic Neuropathy – Companies Involved in Therapeutics Development 17 
Amgen Inc. 17 

Make an enquiry before buying this Report @
BioAxone BioSciences, Inc. 18 
Inotek Pharmaceuticals Corporation 19 
Ironwood Pharmaceuticals, Inc. 20 
PharmatrophiX, Inc. 21 
Quark Pharmaceuticals, Inc. 22 
Regenera Pharma Ltd. 23 
Optic Neuropathy – Therapeutics Assessment 24 
Assessment by Monotherapy Products 24 
Assessment by Target 25 
Assessment by Mechanism of Action 27 
Assessment by Route of Administration 29 
Assessment by Molecule Type 31 
Drug Profiles 33 
BA-240 – Drug Profile 33 
Product Description 33 
Mechanism Of Action 33 
R&D Progress 33 
IWP-953 – Drug Profile 34 
Product Description 34 
Mechanism Of Action 34 
R&D Progress 34 
LM-22A4 – Drug Profile 35 
Product Description 35 
Mechanism Of Action 35 
R&D Progress 35 
Monoclonal Antibodies to Inhibit Sema3A for Glaucoma and Optic Neuropathy – Drug Profile 36 
Product Description 36 
Mechanism Of Action 36 
R&D Progress 36 
NT-501 – Drug Profile 37 
Product Description 37 
Mechanism Of Action 37 
R&D Progress 37 
QPI-1007 – Drug Profile 40 
Product Description 40 
Mechanism Of Action 40 
R&D Progress 40 
RPh-201 – Drug Profile 42 
Product Description 42 
Mechanism Of Action 42 
R&D Progress 42 
Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy – Drug Profile 44 
Product Description 44 
Mechanism Of Action 44 
R&D Progress 44 
Small Molecules for CNS Disorders and Ophthalmology – Drug Profile 45 
Product Description 45 
Mechanism Of Action 45 
R&D Progress 45 
Small Molecules for Neurological and Ophthalmological Diseases – Drug Profile 46 
Product Description 46 
Mechanism Of Action 46 
R&D Progress 46 
Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders – Drug Profile 47 
Product Description 47 
Mechanism Of Action 47 
R&D Progress 47 
Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy – Drug Profile 49 
Product Description 49 
Mechanism Of Action 49 
R&D Progress 49 
trabodenoson – Drug Profile 50 
Product Description 50 
Mechanism Of Action 50 
R&D Progress 50 
WSTB-1 – Drug Profile 53 
Product Description 53 
Mechanism Of Action 53 
R&D Progress 53 
Optic Neuropathy – Dormant Projects 54 
Optic Neuropathy – Product Development Milestones 55 
Featured News & Press Releases 55 
Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant 55 
Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India 55 
Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting 56 
Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications 56 
Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION 57 
Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy 57 
Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies 57 
Appendix 58 
Methodology 58 
Coverage 58 
Secondary Research 58 
Primary Research 58 
Expert Panel Validation 58 
Contact Us 58 
Disclaimer 59

Get this report @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.